{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "LAVA THERAP. B.V. EO-,12", "longName": "LAVA Therapeutics N.V.", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -2.3529458, "regularMarketPrice": 1.66, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.7558824, "fiftyTwoWeekLow": 1.27, "fiftyTwoWeekHigh": 6.8, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.17, "epsForward": -1.92, "epsCurrentYear": -2.39, "priceEpsCurrentYear": -0.69456065, "sharesOutstanding": 26289100, "bookValue": 3.273, "fiftyDayAverage": 1.6118, "fiftyDayAverageChange": 0.04820001, "fiftyDayAverageChangePercent": 0.029904462, "twoHundredDayAverage": 3.06615, "twoHundredDayAverageChange": -1.40615, "twoHundredDayAverageChangePercent": -0.45860445, "marketCap": 43639904, "forwardPE": -0.8645833, "priceToBook": 0.50718, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.2 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": -0.04000008, "regularMarketTime": 1683903602, "regularMarketDayHigh": 1.74, "regularMarketDayRange": "1.66 - 1.74", "regularMarketDayLow": 1.66, "regularMarketVolume": 1150, "regularMarketPreviousClose": 1.7, "bid": 1.64, "ask": 1.7, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.72, "averageDailyVolume3Month": 34, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.39, "fiftyTwoWeekLowChangePercent": 0.30708662, "fiftyTwoWeekRange": "1.27 - 6.8", "fiftyTwoWeekHighChange": -5.1400003, "firstTradeDateMilliseconds": 1617688800000, "symbol": "4PKB.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Yalelaan 60", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 630 00 30 35", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 54, "title": "CEO, Pres & Exec. Director", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 46, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 61, "title": "Chief Devel. Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Paul W. H. I. Parren Ph.D.", "age": 58, "title": "Exec. VP & MD", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}